Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western Kenya
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01810731|
Recruitment Status : Withdrawn (Scientific review positive from 3 manufacturers; internal committees did not support due to deploying new flu vaccines in HIV+ pregnant women in Kenya.)
First Posted : March 13, 2013
Last Update Posted : April 10, 2014
|Condition or disease||Intervention/treatment||Phase|
|Influenza, Human HIV Malaria Tetanus Polio||Biological: Quadrivalent Inactivated Influenza Vaccine (QIV) Biological: Inactivated Polio Vaccine Biological: Double Dose QIV||Phase 2 Phase 3|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Double-Blind, Randomized, Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Standard Dose Quadrivalent Inactivated Influenza Vaccine, and Double Dose Quadrivalent Inactivated Influenza Vaccine in HIV-Infected and HIV-Uninfected Pregnant Women in a Malaria-Endemic Area of Rural Western Kenya|
|Study Start Date :||April 2014|
|Primary Completion Date :||April 2014|
|Study Completion Date :||April 2014|
Experimental: Quadrivalent Influenza Vaccine (QIV)
15µg of each of 2 influenza A strains (H1N1 and H3N2) and 2 influenza B strains in a buffer solution totaling 0.5mL which is administered intramuscularly.
Administered as a single dose on the day of enrollment.
Biological: Quadrivalent Inactivated Influenza Vaccine (QIV)
Other Name: Fluarix, (GlaxoSmithKline Biologicals, Dresden, Germany)
Active Comparator: Inactivated Polio Vaccine
A sterile suspension of three types of poliovirus: Type 1 (Mahoney), Type 2 (MEF1) and Type 3 (Saukett). This vaccine is prepared from types 1, 2 and 3 of poliomyelitis virus cultured on Vero cells, purified and then inactivated by formaldehyde and administered as a 0.5ml intramuscular or subcutaneous injection. A single dose of vaccine will be administered upon enrollment.
Biological: Inactivated Polio Vaccine
Other Name: Imovax, Sanofi Pasteur SA
Experimental: Double Dose QIV
30µg of each of 2 influenza A strains (H1N1 and H3N2) and 2 influenza B strains in a buffer solution totaling 1.0mL which is administered intramuscularly.
Administered as a single dose on the day of enrollment.
Biological: Double Dose QIV
Other Name: Fluarix (GlaxoSmithKline Biologicals, Dresden, Germany)
- Proportion of women with an appropriate rise in Hemagglutination Inhibition (HI) titers [ Time Frame: Enrollment (Day 0) vs. Day 28 for each study arm ]The proportion of standard dose (15 µg) QIV and double dose (30 µg) QIV recipients with a fourfold rise in HI titers or HI titers ≥40 if baseline HI titer <10 compared to the same proportion in controls
- Proportion of infants born to standard dose (15 µg) QIV and double dose (30 µg) QIV recipients with HI titers greater than or equal to 40 in cord blood compared to same in controls. [ Time Frame: At delivery ]
- Number of solicited and unsolicited adverse events post-vaccination by study arm [ Time Frame: During follow-up period, approx. 9 months ]
- Vaccine efficacy of standard dose (15 µg) QIV and double dose (30 µg) QIV in mothers and infants compared to control mothers and infants. [ Time Frame: Entire follow-up period, approx. 9 months ]Incidence of influenza infection will be measured in all participants by surveillance for influenza-like illness (ILI) throughout the study period. Women with fever and cough will be tested for influenza via rRT-PCR of NP/OP swabs. Infants with fever, hypothermia, apnea or any respiratory symptom will also be tested for influenza via rRT-PCR of NP/OP swabs.
- HIV infection and placental antibody transfer [ Time Frame: Delivery ]Compare geometric mean HI titers and geometric mean tetanus antibody titers at delivery in HIV-infected and HIV-uninfected mothers with titers in cord blood.
- Birth weight [ Time Frame: Delivery ]Compare birth weight adjusted for gestational age among standard dose (15 µg) QIV and double dose (30 µg) QIV recipients compared to controls.
- Peripheral and placental parasitemia impact on vaccination [ Time Frame: Day 0 and delivery ]Compare change in geometric mean HI titers from day 0 to day 28 in women with and without peripheral parasitemia at the time of vaccination. Compare amount of passive antibody transfer to infants in cord blood in mothers with and without placental parasitemia
- baseline polio immunity and polio antibody transfer [ Time Frame: day 0 and delivery ]Assess baseline immunity to polio types 1, 2, 3 among all study participants. Assess polio antibody transfer to infants from mothers who did and did not receive IPV.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01810731
|Siaya District Hospital|
|Study Director:||Meredith L McMorrow, MD, MPH||Centers for Disease Control and Prevention|
|Principal Investigator:||Joshua A Mott, PhD||Centers for Disease Control and Prevention Kenya Country Office|
|Principal Investigator:||Nancy Otieno, MS||Kenya Medical Research Institute|
|Study Director:||Marc-Alain Widdowson, VetMB, MSc||Centers for Disease Control and Prevention|